Brandon Twyford

DocwireNews

<a href="https://meetings.asco.org/abstracts-presentations/234365" target="_blank" rel="noopener">The CheckMate 9DW trial, a large-scale phase 3 study</a> led by Peter Robert Galle, MD, PhD, of the University Medical Center Mainz in Germany, compared the efficacy and safety of nivolumab plus ipilimumab to the current standard treatments of lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC). Results were presented at the 2024 American Society of Clinical Oncology Annual Meeting.
Previously, PD-L1 inhibitors like nivolumab have shown promise in treating uHCC, offering better outcomes than sorafenib. However, the overall prognosis for patients with this aggressive cancer remains poor, highlighting the need for more effective and long-lasting therapies. CheckMate 040 demonstrated the potential of nivolumab plus ipilimumab in patients who had already received sorafenib, leading to its approval in the United States.
The CheckMate 9DW trial enrolled treatment-naive adults with uHCC who were ineligible for curative surgery or other local therapies. Patients were randomized to receive either nivolumab plus ipilimumab followed by maintenance nivolumab, or the investigator’s choice of lenvatinib or sorafenib. The primary end point was overall survival (OS).
After a median follow-up of over 35 months, the trial demonstrated a statistically significant improvement in OS for patients treated with nivolumab plus ipilimumab compared with those receiving lenvatinib or sorafenib. The median OS was 23.7 months for the nivolumab plus ipilimumab group compared with 20.6 months for the lenvatinib/sorafenib group. Additionally, the nivolumab plus ipilimumab arm had a higher percentage of patients still alive at 24 months (49% vs 39%).
The immunotherapy combination also yielded superior results in terms of objective response rate. Thirty-six percent of patients in the nivolumab plus ipilimumab group achieved an objective response compared with 13% in the lenvatinib/sorafenib group. Additionally, responses in the nivolumab plus ipilimumab arm were more durable, with a median duration of response of 30.4 months compared with 12.9 months for lenvatinib/sorafenib.
The safety profile of nivolumab plus ipilimumab was similar to what has been observed in other studies. Treatment-related adverse events were comparable between the 2 groups, with the majority being manageable.
The positive results from CheckMate 9DW suggest that nivolumab plus ipilimumab could become a new standard first-line treatment option for patients with unresectable HCC. This immunotherapy combination offers a statistically significant improvement in OS, higher response rates, and durable responses compared with current standard therapies.

Emily Menendez

Tumor Differentiation and Survival Outcomes in Gastric Cancer: The Role of Neoadjuvant Chemotherapy

Gastric Cancer

Rob Dillard

The Importance of Targeting Therapies for Patients With Interstitial Cystitis

Urology

Navigating the Obstacles of Treating Male Patients With Testosterone Replacement Therapy

Latest News

Nivolumab Plus Ipilimumab Shows Promise as First-Line Treatment for Advanced Liver Cancer: CheckMate 9DW

Liver Cancer

CheckMate 9DW trial: Nivolumab plus ipilimumab improves overall survival in unresectable hepatocellular carcinoma

Nivolumab Plus Ipilimumab Shows Promise as First-Line Treatment for Advanced Liver Cancer: CheckMate

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

GEP-NETs

GIST

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe